Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
J Vet Emerg Crit Care (San Antonio) ; 26(4): 488-94, 2016 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-27074368

RESUMO

OBJECTIVE: To evaluate the safety and tolerability of rivaroxaban (RIV), an oral direct factor Xa inhibitory drug, in dogs with presumed primary immune-mediated hemolytic anemia (pIMHA). DESIGN: Prospective, multicenter, positive-controlled, unblinded clinical trial. Client-owned dogs were enrolled between October 2012 and March 2014. SETTING: Private referral centers. ANIMALS: Twenty-four client-owned dogs with pIMHA. Enrolled dogs were randomized in 2 treatment groups to receive by mouth RIV or clopidogrel (CL) and low-dose aspirin (LDA). All dogs were monitored for 90 days from the enrollment in the study. INTERVENTIONS: Enrolled dogs were given a standardized immunosuppressive protocol and RIV or CL and LDA. MEASUREMENTS AND MAIN RESULTS: There was no identifiable adverse drug reaction, evidence of hemorrhage, significant prolongation of prothrombin time or activated partial thromboplastin time, or increase in transfusion requirements associated with RIV therapy compared to CL and LDA in dogs with pIMHA. There was no significant difference between treatment groups with respect to thrombotic events, survival rates to discharge, at 1 month and 3 months from diagnosis. CONCLUSIONS: This study suggests that RIV at a median dose of 0.89 mg/kg by mouth once daily was safe and well tolerated in a small group of dogs with presumed pIMHA able to tolerate oral medications and treated with a standardized immunosuppressive treatment protocol. Conclusions regarding the relative efficacy of RIV as compared to CL and LDA cannot be made due to the small size of the treatment groups and because pharmacodynamic effects were not assessed.


Assuntos
Anemia Hemolítica Autoimune/veterinária , Anti-Inflamatórios não Esteroides/uso terapêutico , Aspirina/uso terapêutico , Doenças do Cão/tratamento farmacológico , Rivaroxabana/uso terapêutico , Administração Oral , Anemia Hemolítica Autoimune/tratamento farmacológico , Animais , Anti-Inflamatórios não Esteroides/administração & dosagem , Aspirina/administração & dosagem , California , Cães , Quimioterapia Combinada , Feminino , Masculino , Estudos Prospectivos , Rivaroxabana/administração & dosagem , Resultado do Tratamento , Washington
3.
Curr Opin Chem Biol ; 8(5): 540-6, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15450498

RESUMO

Nanosized photonic explorers for bioanalysis with biologically localized embedding (PEBBLEs) have been created for the intracellular monitoring of small analytes (e.g. H(+), Ca(2+), Mg(2+), Zn(2+), O(2), K(+), Na(+), Cl(-), OH and glucose). The probes are based on the inclusion of fluorescent analyte-sensitive indicator dyes and analyte-insensitive reference dyes in a polymer (polyacrylamide, polydecylmethacrylate) or sol-gel (silica, ormosil) nanoparticle. The probes are ratiometric, reversible and protected from interaction with the cellular environment, a quality which is of benefit to the integrity of both the cell and the sensor functionalities. Herein we describe two types of PEBBLE sensors, direct measurement sensors and ion correlation sensors, as well as the use of these PEBBLEs in intracellular sensing.


Assuntos
Técnicas Biossensoriais , Líquido Intracelular/química , Nanotecnologia/métodos , Resinas Acrílicas/química , Corantes Fluorescentes , Aumento da Imagem , Prótons , Dióxido de Silício/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...